Revolutionizing Heart Failure Monitoring: CardioTag Offers Noninvasive Accuracy
A new device called CardioTag, worn on the sternum, can measure intracardiac filling pressures. This device alerts users when heart failure is worsening. Researchers conducted a study to evaluate the device’s capabilities. Dr. Liviu Klein, a cardiologist, leads this research at the University of California, San Francisco.
The SEISMIC-HF I study tested the algorithm in CardioTag to estimate pulmonary capillary wedge pressure. It used data from seismocardiography, photoplethysmography, and electrocardiography. The results were compared with pressure readings from the current gold standard, right heart catheterization. The accuracy of CardioTag’s readings closely matched those from existing implantable systems.
Pulmonary artery pressures can rise weeks before heart failure symptoms appear. Dr. Jessica Golbus noted that if patients and physicians are aware of these changes, they can take preventive measures to avoid hospitalization. Current implantable devices, like CardioMEMS, monitor pressures from inside the body. CardioMEMS was approved by the FDA in 2014.
The main advantage of CardioTag is that it is noninvasive. Dr. Golbus emphasized that patients typically prefer such devices. Noninvasive solutions, like CardioTag, can quickly resolve uncertainty in diagnosis and treatment. Invasive devices can be uncomfortable and costly for patients.
How can early detection of pulmonary pressure changes with CardioTag improve patient outcomes in heart failure?
Interview with Dr. Liviu Klein on the Development and Impact of CardioTag for Heart Failure Monitoring
News Directory 3: Thank you for joining us, Dr. Klein. Can you start by explaining what the CardioTag device is and its significance in the management of heart failure?
Dr. Liviu Klein: The CardioTag is an innovative, noninvasive device worn on the sternum designed to measure intracardiac filling pressures. Its primary significance lies in its ability to alert patients and healthcare providers when heart failure is worsening, which can facilitate timely interventions and potentially prevent hospitalizations.
News Directory 3: What motivated your research team to develop CardioTag, and how does it differ from existing monitoring devices?
Dr. Liviu Klein: Our motivation stemmed from the need for more accessible and patient-friendly monitoring solutions. Current devices, like CardioMEMS, are invasive and can be uncomfortable for patients. CardioTag provides an opportunity for continuous monitoring without the invasiveness and associated costs, which is something both patients and physicians have expressed a strong preference for.
News Directory 3: Can you detail the SEISMIC-HF I study and its findings regarding CardioTag?
Dr. Liviu Klein: Certainly. The SEISMIC-HF I study was designed to evaluate the device’s algorithm for estimating pulmonary capillary wedge pressure (PCWP) by leveraging data acquired through seismocardiography, photoplethysmography, and electrocardiography. We found that CardioTag’s readings closely matched those obtained from right heart catheterization, which is the current gold standard. This accuracy is crucial because pulmonary artery pressures can start rising weeks before the onset of heart failure symptoms, allowing for early intervention.
News Directory 3: Dr. Golbus mentioned the importance of awareness regarding changes in pulmonary pressures. How does CardioTag address this issue?
Dr. Liviu Klein: CardioTag empowers both patients and clinicians by providing real-time data on changes in pulmonary pressure. By detecting these changes early, they can take proactive measures rather than waiting until symptoms manifest. This ability to anticipate heart failure worsening is a game-changer in how we approach heart failure management.
News Directory 3: What are the next steps for CardioTag following the SEISMIC-HF I study?
Dr. Liviu Klein: Following the first study, we recognize the need for further research. Our upcoming SEISMIC-HF II study will include a larger and more diverse patient population, which will enhance the representativeness of our data. Ultimately, we plan to conduct a randomized trial to assess how CardioTag affects heart failure management and patient outcomes in a real-world setting.
News Directory 3: Is there anything else you’d like to share about the potential impact of CardioTag on the future of heart failure treatment?
Dr. Liviu Klein: CardioTag represents a significant advancement in noninvasive cardiac monitoring. Its precise measurements of PCWP can help avoid incorrect management strategies often caused by delayed symptom recognition. We are optimistic that, once validated through further studies, CardioTag will become a vital tool in optimizing heart failure care and improving patient quality of life.
News Directory 3: Thank you, Dr. Klein, for sharing your insights on the promising future of heart failure management with CardioTag.
CardioTag offers precise measures of pulmonary capillary wedge pressure, which is the preferred indicator in hospitals. It can prevent incorrect management by providing absolute pressure readings.
However, more research is necessary. The SEISMIC-HF I study only involved patients with heart failure and reduced ejection fraction. Dr. Golbus mentioned that further studies will evaluate CardioTag’s ability to impact patient outcomes. Dr. Klein plans a larger SEISMIC-HF II study to include more patients and sites, enhancing the data’s representation of the wider patient population. After this, he aims to conduct a randomized study to assess the impact of CardioTag on managing heart failure and reducing hospitalizations.